Research Article

The Nod2 Agonist Muramyl Dipeptide Cooperates with the TLR4 Agonist Lipopolysaccharide to Enhance IgG2b Production in Mouse B Cells

Sang-Hoon Lee,1 Jong-Hwan Park,2 and Seok-Rae Park1,3

1Department of Microbiology, Myunggok Medical Research Institute, College of Medicine, Konyang University, Daejeon 35365, Republic of Korea
2Laboratory Animal Medicine, College of Veterinary Medicine, Chonnam National University, Gwangju 61186, Republic of Korea
3Priority Research Center, Myunggok Medical Research Institute, College of Medicine, Konyang University, Daejeon 35365, Republic of Korea

Correspondence should be addressed to Seok-Rae Park; srpark@konyang.ac.kr

Received 24 May 2019; Revised 25 September 2019; Accepted 19 October 2019; Published 26 November 2019

Guest Editor: Riadh Ben Mansour

Copyright © 2019 Sang-Hoon Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Many studies have shown that Toll-like receptors (TLRs) and Nod-like receptors (NLRs) were expressed in B cells and their signaling affects B cell functions. Nonetheless, the roles played by these receptors in B cell antibody (Ab) production have not been completely elucidated. In the present study, we examined the effect of the Nod2 agonist muramyl dipeptide (MDP) in combination with the TLR4 agonist lipopolysaccharide (LPS), a well-known B cell mitogen, on B cell viability, proliferation, and activation, and Ab production by in vitro culture of purified mouse spleen resting B cells. MDP combined with LPS to reinforce B cell viability, proliferation, and activation. Moreover, MDP enhanced LPS-induced IgG2b production, germline γ2b transcript (GLTγ2b) expression, and surface IgG2b expression. In an experiment with Nod2- and TLR4-deficient mouse B cells, we observed that the combined effect of MDP and LPS is dependent on Nod2 and TLR4 receptors. Furthermore, the combined effect on B cell viability and IgG2b switching was not observed in Rip2-deficient mouse cells. Collectively, this study suggests that Nod2 signaling enhances TLR4-activated B cell proliferation, IgG2b switching, and IgG2b production.

1. Introduction

Pattern recognition receptors such as Toll-like receptors (TLRs), Nod-like receptors (NLRs), and C-type lectin receptors (CLRs) recognize specific conserved bacterial structures (pathogen-associated molecular patterns). TLR signaling can directly affect B cell functions, even without the support of T cells [1–4]. We recently reported that TLR1/2 agonist Pam3CSK4 and TLR7 agonist imiquimod directly inhibit IgG1 and IgE class switching, respectively, in activated mouse B cells [5, 6]. In addition, we found that Dectin-1 (a type of CLR) agonist selectively induced IgG1 class switching by TLR4 agonist lipopolysaccharide (LPS)-activated mouse B cells [7, 8]. Many studies have shown that TLR signaling interplays with other receptor signaling such as other TLRs, B cell receptor (BCR), and CD40 signaling in B cells [9–14]. For instance, TLR2 stimulation arrests TLR4 agonist LPS-promoted B cell maturation [15]; BCR signaling synergizes with TLR signaling for activation-induced cytidine deaminase (AID) expression and Ig class switch recombination (CSR) by B cells [16]. Thus, TLRs play various roles in B cell activation, differentiation, and function.

However, the roles played by NLRs (Nod1, Nod2, NLRC4, NLRP3, etc.) in B cells remain to be elucidated. The effects of Nod1 and Nod2 stimulation on B cell activation have been investigated in only a few studies: Cohen and Parant reported that Nod2 agonist muramyl dipeptide (MDP) increases surface Ig (membrane κ-light chain) expression and enhances the response to LPS in the mouse pre-B cell line 70Z/3 [17]; Petterson et al. reported that Nod1 or Nod2 stimulation augments BCR- or TLR-induced human B cell activation (proliferation, viability,
and expression of cell surface markers) independently of physical T cell assistance [18, 19].

In the present study, to further elucidate the role of Nod2 in B cell response, we directly stimulated mouse resting B cells with MDP in the absence and presence of LPS in vitro and analyzed B cell viability, proliferation, activation, antibody (Ab) production, and Ig class switching.

2. Materials and Methods

2.1. Animals. Wild-type (WT) C57BL/6 mice were purchased from Damool Science (Daejeon, Korea). TLR4-deficient (Tlr4−/−), Nod2-deficient (Nod2−/−), and Rip2-deficient (Rip2−/−) mice with a C57BL/6 background were purchased from Jackson Laboratory (Bar Harbor, ME, USA). Mice were maintained on an 8:16 h light:dark cycle in an animal environmental control chamber. Eight- to twelve-week-old mice were used, and animal care was provided in accordance with the guidelines of the Institutional Animal Care and Use Committee of Konyang University.

2.2. Cell Culture and Reagents. The mouse B cell lines L10A6.2 (surface μ+, mature B cell line) and A20.3 (surface γ2a+) were provided by Dr. J. Stavnezer (University of Massachusetts Medical School, Worcester, MA, USA). The mouse B lymphoma cell line CH12F3-2A (surface μ+) was provided by Dr. T. Honjo (Kyoto University, Kyoto, Japan). Mouse spleen resting B cells were obtained by depletion of CD43+ cells using anti-CD43 microbeads and high-gradient magnetic cell separation according to the manufacturer’s instruction (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany) as previously described [5]. The purity of resting B cells (CD43− B220+) was assessed using FACSCalibur (BD Biosciences, San Jose, CA, USA) following staining of the cells with anti-CD43 FITC (eBioscience, San Diego, CA, USA) and anti-B220 PE (BD Biosciences) (Supplementary Figure 1(a)). The cells were cultured at 37°C in a humidified CO2 incubator (Forma Scientific, Marietta, OH, USA) in RPMI-1640 medium (Welgene, Daegu, Korea) supplemented with 10% fetal bovine serum (PAA Laboratories, Etobicoke, ON, Canada). The cells were stimulated with LPS (ultrapure LPS, E. coli 0111:B4; InvivoGen, San Diego, CA, USA), MDP (InvivoGen), and iE-DAP (InvivoGen). The mouse macrophage cell line RAW264.7 was cultured in DMEM (Welgene) containing 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 10% fetal bovine serum in a humidified CO2 incubator. Anti-mouse IgG2b-
PE and anti-mouse IgG3-PE were purchased from Southern Biotech (Birmingham, AL, USA). Anti-mouse IgM-PE was obtained from eBioscience.

2.3. Cell Viability, Proliferation, and Activation Assays. Cell viability was determined using the EZ-Cytox cell viability assay (DaeilLab Service Co., Ltd., Seoul, Korea) according to the manufacturer’s instructions [8]. For the cell proliferation assay, purified mouse resting B cells were labeled with CFSE (eBioscience) and then supplemented with MDP, iE-DAP, and LPS. CFSE dilution was measured by counting 10,000 cells with the FACSCalibur. For the cell activation assay, cultured cells were stained with anti-CD69-FITC (BD Biosciences), and the expression levels were analyzed by flow cytometry (FACSCalibur).

2.4. Isotype-Specific ELISAs. Antibodies produced in B cell cultures were detected using isotype-specific ELISAs as previously described [8].

2.5. RNA Isolation and RT-PCR. RNA isolation and RT-PCR were performed as previously described [6]. The PCR primers (Supplementary Table 1) were synthesized by Bioneer (Daejeon, Korea). PCR for β-actin was performed in parallel to normalize for cDNA concentrations within each set of samples. PCR products were resolved by electrophoresis on 2% agarose gels. Semiquantitative RT-PCR analysis was performed using cDNA dilutions.

2.6. Flow Cytometric Analysis. Surface staining was performed with anti-mouse IgG2b-PE, anti-mouse IgG3-PE,
or anti-mouse IgM-PE in the dark for 30 min at 4°C, and surface Ig-expressing B cells were analyzed by flow cytometry (FACSCalibur). Dead cells were excluded from analysis using Zombie Red™ Fixable Viability Kit according to the manufacturer’s instruction (BioLegend, San Diego, CA).

2.7. Statistical Analysis. Statistical differences between experimental groups were determined by analysis of variances. All p values were calculated using unpaired 2-tailed Student’s t-tests to assess statistical significance.

3. Results and Discussion

3.1. Dosage Effect of Nod2 Agonist MDP on B Cell Viability and Proliferation. First, to determine the direct effect of the Nod2 agonist MDP on B cell viability and proliferation, we purified resting B cells from mouse spleen (Supplementary Figure 1(a)) and treated them with MDP. The resting B cells expressed Nod1 and Nod2 as well as TLR4 (Supplementary Figure 1(b)). The RAW264.7 mouse macrophage cell line was used as a positive control for TLR and NLR expression. Resting B cells could not survive in the absence of stimuli in vitro and died (Figure 1(a), white bars). MDP treatment sustained B cell viability but did not increase it in a dose-dependent manner. MDP very slightly induced B cell proliferation (Figure 1(b)). However, MDP alone did not induce any Ab production (data not shown). These results suggest that MDP sustains B cell viability, but MDP itself hardly induces B cell proliferation and plasma cell differentiation.

3.2. Nod2 Agonist MDP but Not Nod1 Agonist iE-DAP Combines with TLR4 Agonist LPS to Induce B Cell Viability and Proliferation and IgG2b Production. New functions in innate immune cells have been reported for the crosstalk between TLRs and NLRs [20–22]. There is a synergistic stimulation of human monocytes and dendritic cells by TLR4 and Nod1- and Nod2-activating agonists [23]. Furthermore, Nod2 is involved in TLR4-mediated signaling of inflammation regulation [24, 25]. LPS stimulates TLR4 and is a well-known mitogen for mouse B cells [26, 27]. TLR4 on B cells recognizes LPS and stimulates B cell proliferation, differentiation, and Ig CSR. LPS in vitro stimulation
increases IgG2b and IgG3 production through IgG2b and IgG3 class switching, respectively, by mouse B cells [4, 28–33]. Therefore, we investigated the combined effect of TLR4 agonist LPS and Nod2 agonist MDP or Nod1 agonist iE-DAP on B cell viability, proliferation, activation, and Ab production. Resting B cells were stimulated with MDP or iE-DAP in the presence or absence of LPS. After 2 and 3 days of culture, LPS-induced cell viability was significantly enhanced by MDP but not by iE-DAP (Figure 2(a)). In addition, MDP reinforced LPS-induced cell proliferation (Figure 2(b)). These results indicate that MDP combined with LPS to induce B cell viability and proliferation, while iE-DAP does not. Further, MDP enhanced LPS-induced expression of CD69, which is an activation marker (Figure 2(c)). Next, we examined the effect of MDP on LPS-induced Ab production, particularly IgG2b and IgG3 production. MDP increased LPS-induced IgG2b production but decreased LPS-induced IgG3 and IgG1 production.

![Figure 4: Combined effects of LPS and MDP on surface Ig expression. Resting B cells were stimulated with LPS (1 μg/mL) and MDP (10 μg/mL). After 4 days of culture, cells were stained with anti-IgG2b-PE, anti-IgG3-PE, or anti-IgM-PE, and surface Ig expression was analyzed by flow cytometry.](image-url)
Figure 5: Continued.
iE-DAP had no significant effect on LPS-induced Ab production. Instead, iE-DAP decreased LPS-induced IgG2b production. These results indicate that MDP combines with LPS to selectively induce IgG2b production.

### 3.3. MDP Combines with LPS to Induce Germline γ2b Transcripts and Surface IgG2b Expression

The transcription of germline transcripts (GLT) is a prerequisite for subsequent Ig CSR [34–36]. Therefore, GLT expression can serve as a marker of Ig class switching. LPS induces the expression of GLTγ2b as well as that of GLTγ3 [34, 37, 38]. To evaluate the effect of MDP on LPS-induced IgG2b class switching, we examined whether LPS and MDP together induce the expression of germline γ2b transcripts (GLTγ2b) and surface IgG2b. Resting B cells were stimulated with MDP and iE-DAP in the presence or absence of LPS, whereas MDP did not affect LPS-induced GLTγ3 and GLTγ1 expression (Figure 3). In contrast, iE-DAP neither had any effect on LPS-induced GLTγ2b expression nor on GLTγ3 and GLTγ1 expression. Because AID is an essential enzyme for class switching [39], we assessed its expression. MDP did not affect LPS-induced AID mRNA expression (Figure 3). In addition, MDP selectively enhanced LPS-induced surface IgG2b expression (Figure 4). MDP alone did not induce surface IgG2b expression (data not shown). Collectively, these
results indicate that LPS and MDP together induce IgG2b production through increasing IgG2b class switching.

3.4. Combination Effect of LPS and MDP Is Abrogated in TLR4- and Nod2-Deficient B Cells. LPS and MDP are specific agonists for TLR4 and Nod2, respectively. Therefore, we examined whether the effects of LPS and MDP on B cell responses are dependent on their specific receptors by comparing B cells from WT and TLR4-deficient (Tlr4−/−) or Nod2-deficient (Nod2−/−) mice. WT, TLR4−, and Nod2-deficient B cells were stimulated with MDP or iE-DAP in the presence or absence of LPS, and cell viability, cell proliferation, and Ab production were measured (Figure 5). In TLR4-deficient B cells, LPS did not induce cell viability and proliferation (Figure 5(a), gray bars). This finding confirms that B cell proliferation by LPS is dependent on TLR4. In Nod2-deficient B cells, MDP did not enhance LPS-induced cell viability and proliferation (Figure 5(a), black bars).
indicates that MDP can enhance LPS-induced B cell proliferation through Nod2. Next, we examined the effects of LPS and MDP on Ab production in TLR4- and Nod2-deficient B cells. TLR4-deficient B cells did not produce all Abs production upon stimulation of LPS (Figure 5(b)). In Nod2-deficient B cells, MDP did not increase LPS-induced IgG2b production. Furthermore, MDP did not increase LPS-induced GLT2b expression in Nod2-deficient B cells (Figure 5(c)). These results suggest that the combined effect of LPS and MDP on B cell proliferation and IgG2b production is dependent on their receptors, TLR4 and Nod2. In addition, we investigated the effects of LPS and MDP on B cell responses in receptor-interacting protein 2 (Rip2)-deficient (Rip2−/−) B cells (Figure 6), because Rip2 is a critical mediator of Nod2 signaling in innate and adaptive immune responses [40–43]. MDP neither reinforced LPS-induced cell viability nor increased cell proliferation (Figure 6(a)), IgG2b production (Figure 6(b)), or GLT2b expression (Figure 6(c)) in Rip2−/− B cells. Thus, Nod2-Rip2-mediated signaling could cooperatively play a critical role in LPS-induced B cell responses. However, the underlying molecular mechanisms remain to be determined.

4. Conclusions

Our present observations demonstrate that direct stimulation of Nod2 selectively enhances TLR4 agonist LPS-induced IgG2b production by enhancing IgG2b class switching in mouse B cells. IgG2b is particularly important early in the immune response, when T cell support may be limited (i.e., T-independent response), and provides early FcγR-mediated effector functions and efficient complement activation through binding on C1q [31, 44–46]. Consequently, Nod2 agonist MDP can be used as B cell adjuvant to protect from fast-replicating bacterial infection through enhancing direct B cell activation and IgG2b production independent of T cells and BCR stimulation.

Abbreviations

TLR: Toll-like receptor
NLR: Nod-like receptor
LPS: Lipopolysaccharide
MDP: Muramyl dipeptide
Ab: Antibody
GLT: Germline transcripts
CSR: Class switch recombination

Data Availability

All data supporting the findings of this study, including its supplementary information files, are available from the corresponding author upon reasonable request.

Disclosure

The preliminary results of the current work have been presented as poster presentation on the 15th International Congress of Immunology 2013 (Milan, Italy; Abstract no.: P3.07.27). Lee Sang-Hoon’s present address is the Curocell Inc., Daejeon, Republic of Korea.

Conflicts of Interest

The authors declare no financial or commercial conflict of interest.

Acknowledgments

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (MEST) (NRF-2016R1A1B4003558) and the Priority Research Centers Program through the NRF funded by the MEST (NRF-2017R1A6A1A03015713).

Supplementary Materials

Supplementary Table 1: RT-PCR primers. Supplementary Figure 1: Purity of resting B cells and expression of TLR4, Nod1, and Nod2 in the resting B cells. (a) Purity of isolated mouse spleen resting B cells (CD43-B220+) was measured from the resting B cells and the indicated cell lines. The levels of TLR4, Nod1, and Nod2 mRNA were measured by RT-PCR. (Supplementary Materials)

References

[1] N. Liu, N. Ohnishi, L. Ni, S. Akira, and K. B. Bacon, “CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells,” Nature Immunology, vol. 4, no. 7, pp. 687–693, 2003.
[2] T. Kusunoki, M. Sugai, H. Gonda et al., “CpG inhibits IgE class switch recombination through suppression of NFκB activity, but not through Id2 or Bcl6,” Biochemical and Biophysical Research Communications, vol. 328, no. 2, pp. 499–506, 2005.
[3] E. Shen, L. Lu, and C. Wu, “TLR7/8 ligand, R-848, inhibits IgE synthesis by acting directly on B lymphocytes,” Scandinavian Journal of Immunology, vol. 67, no. 6, pp. 560–568, 2008.
[4] I. Bekeredjian-Ding and G. Jego, “Toll-like receptors – sentries in the B-cell response,” Immunology, vol. 128, no. 3, pp. 311–323, 2009.
[5] S. H. Lee and S. R. Park, “Toll-like receptor 1/2 agonist Pam3CSK4 suppresses lipopolysaccharide-driven IgG1 production while enhancing IgG2a production by B cells,” Immune Network, vol. 18, no. 1, article e10, 2018.
[6] H. K. Yoon, Y. S. Shim, P. H. Kim, and S. R. Park, “The TLR7 agonist imiquimod selectively inhibits IL-4-induced IgE production by suppressing IgG1/IgE class switching and germline ε transcription through the induction of BCL6 expression in B cells,” Cellular Immunology, vol. 338, pp. 1–8, 2019.
[7] B. S. Seo, S. H. Lee, J. E. Lee, Y. C. Yoo, J. Lee, and S. R. Park, “Dectin-1 stimulation selectively reinforces LPS-driven IgG1 production by mouse B cells,” Immune Network, vol. 13, no. 5, pp. 205–212, 2013.
[8] B. S. Seo, H. Y. Park, H. K. Yoon, Y. C. Yoo, J. Lee, and S. R. Park, “Dectin-1 agonist selectively induces IgG1 class switching by LPS-activated mouse B cells,” Immunology Letters, vol. 178, pp. 114–121, 2016.
[9] S. Minguet, E. P. Dopfer, C. Pollmer et al., “Enhanced B-cell activation mediated by TLR4 and BCR crosstalk,” European Journal of Immunology, vol. 38, no. 9, pp. 2475–2487, 2008.

[10] E. J. Pone, H. Zan, J. Zhang, A. Al-Qahtani, Z. Xu, and P. Casali, “Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses,” Critical Reviews in Immunology, vol. 30, no. 1, pp. 1–29, 2010.

[11] E. Boeglin, C. R. Smulski, S. Brun, S. Milosevic, P. Schneider, and S. Fournel, “Toll-like receptor agonists synergize with CD40L to induce either proliferation or plasma cell differentiation of mouse B cells,” PLoS One, vol. 6, no. 10, article e25542, 2011.

[12] S. Jain, S. B. Chodisetti, and J. N. Agrewala, “CD40 signaling synergizes with TLR-2 in the BCR independent activation of resting B cells,” PLoS One, vol. 6, no. 6, article e20651, 2011.

[13] E. J. Pone, Z. Xu, C. A. White, H. Zan, and P. Casali, “B cell TLRs and induction of immunoglobulin class-switch DNA recombination,” Frontiers in Bioscience, vol. 17, no. 7, pp. 2594–2615, 2012.

[14] E. J. Pone, Z. Lou, T. Lam et al., “B cell TLR1/2, TLR4, TLR7 and TLR9 interact in induction of class switch DNA recombination: modulation by BCR and CD40, and relevance to T-independent antibody responses,” Autoimmunity, vol. 48, no. 1, pp. 1–12, 2015.

[15] E. A. Hayashi, S. Akira, and A. Nobrega, “Role of TLR in B cell development: signaling through TLR4 promotes B cell maturation and is inhibited by TLR2,” Journal of Immunology, vol. 174, no. 11, pp. 6639–6647, 2005.

[16] E. J. Pone, J. Zhang, T. Mai et al., “BCR signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-κB pathway,” Nature Communications, vol. 3, no. 1, p. 767, 2012.

[17] L. Y. Cohen and M. A. Parant, “Differential regulation of surface immunoglobulin expression by various muramyl dipeptides in a murine pre-B cell line,” Immunity Letters, vol. 45, no. 3, pp. 210–214, 1995.

[18] T. Petterson, J. Jendholm, A. Mansson, A. Bjartell, K. Riesbeck, and L. O. Cardell, “Effects of NOD-like receptors in human B lymphocytes and crosstalk between NOD1/NOD2 and toll-like receptors,” Journal of Leukocyte Biology, vol. 89, no. 2, pp. 177–187, 2011.

[19] L. A. J. O’Neill, “Editorial: Synergism between NOD-like receptors and Toll-like receptors in human B lymphocytes,” Journal of Leukocyte Biology, vol. 89, no. 2, pp. 173–175, 2011.

[20] M. S. Lee and Y. J. Kim, “Signaling pathways downstream of pattern-recognition receptors and their cross talk,” Annual Review of Biochemistry, vol. 76, pp. 447–480, 2007.

[21] D. M. Underhill, “Collaboration between the innate immune receptors dectin-1, TLRs, and Nods,” Immunological Reviews, vol. 219, pp. 75–87, 2007.

[22] K. Dolasia, M. K. Bish, G. Pradhan, A. Udgata, and S. Mukhopadhyay, “TLRs/NLRs: shaping the landscape of host immunity,” International Reviews of Immunology, vol. 37, no. 1, pp. 3–19, 2018.

[23] J. H. Fritz, S. E. Girardin, C. Fitting et al., “Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists,” European Journal of Immunology, vol. 35, no. 8, pp. 2459–2470, 2005.

[24] W. H. Tsai, D. Y. Huang, Y. H. Yu, C. Y. Chen, and W. W. Lin, “Dual roles of NOD2 in TLR4-mediated signal transduction and -induced inflammatory gene expression in macrophages,” Cellular Microbiology, vol. 13, no. 5, pp. 717–730, 2011.

[25] H. Kim, Q. Zhao, H. Zheng, X. Li, T. Zhang, and X. Ma, “A novel crosstalk between TLR4- and NOD2-mediated signaling in the regulation of intestinal inflammation,” Scientific Reports, vol. 5, no. 1, article 12018, 2015.

[26] G. Janossy, J. Snajdr, and M. Simak-Ellis, “Patterns of B-lymphocyte gene expression elicited by lipopolysaccharide mitogen,” Immunology, vol. 30, no. 6, pp. 799–810, 1976.

[27] A. Poltorak, X. He, I. Smirnova et al., “Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene,” Science, vol. 282, no. 5396, pp. 2085–2088, 1998.

[28] D. Yuan and E. S. Vitetta, “Structural studies of cell surface and secreted IgG in LPS-stimulated murine B cells,” Molecular Immunology, vol. 20, no. 4, pp. 367–375, 1983.

[29] C. Esser and A. Radbruch, “Immunoglobulin class switching: molecular and cellular analysis,” Annual Review of Immunology, vol. 8, pp. 717–735, 1990.

[30] C. M. Snapper and J. J. Mond, “Towards a comprehensive view of immunoglobulin class switching,” Immunology Today, vol. 14, no. 1, pp. 15–17, 1993.

[31] E. K. Deenick, J. Hashold, and P. D. Hodgkin, “Switching to IgG3, IgG2b, and IgA is division linked and independent, revealing a stochastic framework for describing differentiation,” The Journal of Immunology, vol. 163, no. 9, pp. 4707–4714, 1999.

[32] Q. Pan-Hammarström, Y. Zhao, and L. Hammarström, “Class switch recombination: a comparison between mouse and human,” Advances in Immunology, vol. 93, pp. 1–61, 2007.

[33] F. J. Quintana, A. Solomon, I. R. Cohen, and G. Nussbaum, “Induction of IgG3 to LPS via toll-like receptor 4 co-stimulation,” PLoS One, vol. 3, no. 10, article e3509, 2008.

[34] E. Severinson, C. Fernandez, and J. Stavnezer, “Induction of germ-line immunoglobulin heavy chain transcripts by mitogens and interleukins prior to switch recombination,” European Journal of Immunology, vol. 20, no. 5, pp. 1079–1084, 1990.

[35] J. Stavnezer, “Immunoglobulin class switching,” Current Opinion in Immunology, vol. 8, no. 2, pp. 199–205, 1996.

[36] J. Stavnezer, “Molecular processes that regulate class switching,” Current Topics in Microbiology and Immunology, vol. 245, no. 2, pp. 127–168, 2000.

[37] S. Lutzker, P. Rothman, R. Pollock, R. Coffman, and F. W. Alt, “Mitogen- and IL-4-regulated expression of germ-line Ig γ2b transcripts: Evidence for directed heavy chain class switching,” Cell, vol. 53, no. 2, pp. 177–184, 1988.

[38] P. Rothman, S. Lutzker, B. Gorham, V. Stewart, R. Coffman, and F. W. Alt, “Structure and expression of germ-line immunoglobulin γ3 heavy chain gene transcripts: implications for mitogen and lymphokine directed class-switching,” International Immunology, vol. 2, no. 7, pp. 621–627, 1990.

[39] M. Muramatsu, K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shinkai, and T. Honjo, “Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme,” Cell, vol. 102, no. 5, pp. 553–563, 2000.

[40] A. I. Chin, P. W. Dempsey, K. Bruhn, J. F. Miller, Y. Xu, and G. Cheng, “Involvement of receptor-interacting protein 2 in
innate and adaptive immune responses,” *Nature*, vol. 416, no. 6877, pp. 190–194, 2002.

[41] K. Kobayashi, N. Inohara, L. D. Hernandez et al., “RICK/-Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems,” *Nature*, vol. 416, no. 6877, pp. 194–199, 2002.

[42] J. G. Magalhaes, J. Lee, K. Geddes, S. Rubino, D. J. Philpott, and S. E. Girardin, “Essential role of Rip2 in the modulation of innate and adaptive immunity triggered by Nod1 and Nod2 ligands,” *European Journal of Immunology*, vol. 41, no. 5, pp. 1445–1455, 2011.

[43] Q. Gong, Z. Long, F. L. Zhong et al., “Structural basis of RIP2 activation and signaling,” *Nature Communications*, vol. 9, no. 1, article 4993, 2018.

[44] R. R. McKendall and W. Woo, “Murine IgG subclass responses to herpes simplex virus type 1 and polypeptides,” *The Journal of General Virology*, vol. 69, no. 4, pp. 847–857, 1988.

[45] S. A. da Silveira, S. Kikuchi, L. Fossati-Jimack et al., “Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody,” *The Journal of Experimental Medicine*, vol. 195, no. 6, pp. 665–672, 2002.

[46] A. M. Collins, “IgG subclass co-expression brings harmony to the quartet model of murine IgG function,” *Immunology and Cell Biology*, vol. 94, no. 10, pp. 949–954, 2016.